Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gordon C Jayson

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endotheliumMelissa K Whitworth, Alison C Backen, Andrew R Clamp, et al.
BMC Palliative Care|December 31, 2019
Palliative home parenteral nutrition in patients with ovarian cancer and malignant bowel obstruction: experiences of women and family caregiversAnne Marie Sowerbutts, Simon Lal, Jana Sremanakova, et al.
Gynecologic Oncology|January 15, 2020
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trialRobert D Morgan, Susana Banerjee, Marcia Hall, et al.
Cancers|January 11, 2024
Real-World Concordance between Germline and Tumour <i>BRCA1/2</i> Status in Epithelial Ovarian CancerRobert D Morgan, George J Burghel, Helene Schlecht, et al.
BMC Medicine|February 11, 2022
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trialRobert D Morgan, Cristina Ferreras, Isabel Peset, et al.
British Journal of Cancer|May 14, 2022
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumoursAya El Helali, Ruth Plummer, Gordon C Jayson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2020
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyOsnat Elyashiv, Jonathan Ledermann, Gita Parmar, et al.
Lancet (London, England)|October 5, 2010
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialGordon J S Rustin, Maria E L van der Burg, Clare L Griffin, et al.
Journal of Medical Genetics|August 14, 2025
Homologous recombination deficiency in unselected cases of high-grade ovarian carcinomaRobert D Morgan, George J Burghel, Joseph Shaw, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2005
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancerGordon C Jayson, Clive Mulatero, Malcolm Ranson, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 17, 2005
Regulation of fibroblast growth factor-2 activity by human ovarian cancer tumor endotheliumMelissa K Whitworth, Alison C Backen, Andrew R Clamp, et al.
BMC Palliative Care|December 31, 2019
Palliative home parenteral nutrition in patients with ovarian cancer and malignant bowel obstruction: experiences of women and family caregiversAnne Marie Sowerbutts, Simon Lal, Jana Sremanakova, et al.
Gynecologic Oncology|January 15, 2020
Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trialRobert D Morgan, Susana Banerjee, Marcia Hall, et al.
Cancers|January 11, 2024
Real-World Concordance between Germline and Tumour <i>BRCA1/2</i> Status in Epithelial Ovarian CancerRobert D Morgan, George J Burghel, Helene Schlecht, et al.
BMC Medicine|February 11, 2022
c-MET/VEGFR-2 co-localisation impacts on survival following bevacizumab therapy in epithelial ovarian cancer: an exploratory biomarker study of the phase 3 ICON7 trialRobert D Morgan, Cristina Ferreras, Isabel Peset, et al.
British Journal of Cancer|May 14, 2022
A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumoursAya El Helali, Ruth Plummer, Gordon C Jayson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|October 24, 2020
ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapyOsnat Elyashiv, Jonathan Ledermann, Gita Parmar, et al.
Lancet (London, England)|October 5, 2010
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialGordon J S Rustin, Maria E L van der Burg, Clare L Griffin, et al.
Journal of Medical Genetics|August 14, 2025
Homologous recombination deficiency in unselected cases of high-grade ovarian carcinomaRobert D Morgan, George J Burghel, Joseph Shaw, et al.
European Journal of Cancer (Oxford, England : 1990)|March 2, 2005
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancerGordon C Jayson, Clive Mulatero, Malcolm Ranson, et al.
Pageof 13